Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2017

View Archived Issues

Bristol-Myers Squibb initiates phase I trial of BMS-986235 in healthy subjects

Roche opens enrollment in phase III trial of polatuzumab vedotin with R-CHP for DLBCL

Akesobio studies AK-104 in advanced solid tumors

Regeneron initiates phase II study of REGN-2477 for fibrodysplasia ossificans progressiva

Phase II/III data presented for fexinidazole in African T. brucei gambiense trypanosomiasis

Patient enrollment ongoing in phase III study of HD-201 in patients with HER2+ early breast cancer

Servier Canada enters a new partnership with CQDM

Theralase reports on new anticancer vaccine

Initiation of phase I/II study of IMM-529 in patients with Clostridium difficile infection

First preclinical data presented for AG-10 in ATTR cardiomyopathy

Etanercept biosimilar LBEC-0101 demonstrates equivalence to original

Antimalarial SJ-733 safe in first-in-human study

New PROFYLE program in Canada aims to accelerate research breakthroughs in pediatric cancer

Imugene raises financing to advance HER-Vaxx development

Crown Bioscience and DSI collaborate on implantable device to monitor blood glucose in research

INHALE study of Amikacin Inhale does not meet primary endpoint

Alzinova advances preclinical work on ALZ-101

ChAd3-EBO-Z Ebola vaccine well tolerated and immunogenic in children

Puma Biotechnology and Specialised Therapeutics Asia sign commercialization agreement for Nerlynx

Esteve describes novel dual voltage-gated calcium channel ligands and NET inhibitors

New phase I trial explores use of AZD-1775 in head and neck cancer

New proteinase-activated PAR2 receptor antagonists identified at AstraZeneca

Boehringer Ingelheim patents semicarbazide-sensitive amine oxidase inhibitors

AstraZeneca presents novel ataxia telangiectasia mutated kinase inhibitors

Arvinas and Macroceutics establish multi-target screening collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...